Sulfamethoxazole

Sulfamethoxazole is an antibiotic of the sulfonamide family. It blocks a bacterial enzyme, dihydropteroate synthase, by taking the place of para-aminobenzoic acid (PABA), the molecule this enzyme normally uses. By occupying that site, it halts the production of folate, specifically dihydrofolic acid, which the bacterium needs. Deprived of folate, it can no longer produce its DNA or multiply.

Sulfamethoxazole is almost always combined with trimethoprim, a pairing known as co-trimoxazole. Trimethoprim blocks the next step of the same pathway: it inhibits dihydrofolate reductase and prevents the formation of tetrahydrofolate. The two molecules thus close two successive locks in the folate chain. This joint action makes the effect bactericidal, capable of killing the bacterium and not merely slowing its growth.

Co-trimoxazole covers a broad range of infections. It is prescribed for urinary tract infections, acute exacerbations of chronic bronchitis and traveller’s diarrhoea. It also remains a reference treatment for Pneumocystis jirovecii pneumonia, a lung infection that mainly affects people with weakened immune systems.

Its indications go beyond common infections. The drug is also used for the prevention of that same Pneumocystis pneumonia in at-risk patients, as well as for the treatment of toxoplasmosis. This versatility explains its long-standing and enduring place in the antibiotic arsenal.

Co-trimoxazole is taken orally, with or without food. Each dose should be accompanied by a large glass of water, at least 240 mL, to ease the drug’s passage and protect the kidneys. The half-life of sulfamethoxazole is around 10 hours and that of trimethoprim 8 to 10 hours, which explains a dosing rhythm spread across the day.

Consistency is what makes an antibiotic effective. Keep to the times and duration set by your doctor, even if the symptoms ease before the end. Do not stop it on your own: a shortened treatment lets the most resistant bacteria survive and encourages relapses.

The most common side effects affect digestion and the skin. On the digestive side, there is nausea, vomiting and loss of appetite. On the skin, allergic reactions appear, in the form of a rash or hives. These are the most frequent manifestations during treatment.

Serious reactions do exist, but they remain rare. Stevens-Johnson syndrome, a severe disorder of the skin and mucous membranes, and agranulocytosis, a sudden drop in white blood cells, are among the complications that call for stopping the drug and seeking immediate medical advice. Any widespread rash, fever or damage to the mucous membranes should raise the alarm.

Because it blocks the folate pathway, co-trimoxazole can cause signs of folic acid deficiency, up to megaloblastic anaemia in which red blood cells become large and poorly functional. Older people are more exposed to it. This effect is reversible: folinic acid corrects it. Folate takes part precisely in the formation of red blood cells and the production of DNA.

The second point concerns potassium. Trimethoprim, especially at high doses, raises blood potassium in a gradual and reversible way in a substantial number of patients. Hyperkalaemia can also occur at usual doses in cases of kidney failure, disorders of potassium metabolism or the use of other drugs that raise potassium. The doctor monitors this parameter in at-risk situations.

Several combinations call for particular vigilance. Sulfamethoxazole slows the metabolism of warfarin through the CYP2C9 enzyme: the INR and the risk of bleeding increase. With methotrexate, toxicity and the risk of megaloblastic anaemia rise. The drug also slows the elimination of phenytoin and lengthens its half-life by around 39%. Finally, combined with angiotensin-converting enzyme inhibitors, angiotensin receptor blockers or spironolactone, it can lead to serious hyperkalaemia.

These risks justify a precise prescribing framework. Co-trimoxazole is contraindicated in cases of megaloblastic anaemia due to folate deficiency, liver damage, kidney failure, in newborns under 6 weeks and with dofetilide. In kidney failure, the half-life of sulfamethoxazole can climb to 20 or 50 hours, hence the dose adjustment. Monitoring relies on periodic complete blood counts and electrolyte panels in at-risk patients, sometimes preceded by a measurement of urea and creatinine.